UA85099C2 - Liposomal irinotecan preparation - Google Patents

Liposomal irinotecan preparation

Info

Publication number
UA85099C2
UA85099C2 UAA200614105A UAA200614105A UA85099C2 UA 85099 C2 UA85099 C2 UA 85099C2 UA A200614105 A UAA200614105 A UA A200614105A UA A200614105 A UAA200614105 A UA A200614105A UA 85099 C2 UA85099 C2 UA 85099C2
Authority
UA
Ukraine
Prior art keywords
irinotecan
mol
preparation
closed
blood
Prior art date
Application number
UAA200614105A
Other languages
English (en)
Ukrainian (uk)
Inventor
Кейсуке Йосино
Сигенори Нозава
Масаси Исозаки
Сейго Савада
Икуо Като
Original Assignee
Кабусики Кайся Якулт Хонса
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кабусики Кайся Якулт Хонса filed Critical Кабусики Кайся Якулт Хонса
Publication of UA85099C2 publication Critical patent/UA85099C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к липосомам иринотекана. Липосома сформирована липидной мебраной, внешняя поверхность которой модифицирована гидрофильным полимером, а иринотекан инкапсулирован в концентрации по меньшей мере 0,1 мол./мол. (моль лекарственного средства/моль общего липида мембраны).
UAA200614105A 2004-06-01 2005-05-31 Liposomal irinotecan preparation UA85099C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004163742 2004-06-01

Publications (1)

Publication Number Publication Date
UA85099C2 true UA85099C2 (en) 2008-12-25

Family

ID=35462721

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200614105A UA85099C2 (en) 2004-06-01 2005-05-31 Liposomal irinotecan preparation

Country Status (24)

Country Link
US (1) US7846473B2 (ru)
EP (1) EP1752150B1 (ru)
JP (1) JP4885715B2 (ru)
KR (1) KR100889139B1 (ru)
CN (1) CN1960729B (ru)
AP (1) AP2255A (ru)
AR (1) AR049137A1 (ru)
AU (1) AU2005249314B2 (ru)
BR (1) BRPI0511753A (ru)
CA (1) CA2567857C (ru)
CR (1) CR8768A (ru)
EA (1) EA011612B1 (ru)
EC (1) ECSP067041A (ru)
ES (1) ES2594621T3 (ru)
GE (1) GEP20094620B (ru)
IL (1) IL179558A0 (ru)
MX (1) MXPA06013874A (ru)
NO (1) NO20066074L (ru)
NZ (1) NZ551748A (ru)
TN (1) TNSN06395A1 (ru)
TW (1) TWI362931B (ru)
UA (1) UA85099C2 (ru)
WO (1) WO2005117878A1 (ru)
ZA (1) ZA200610204B (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101376895B1 (ko) 2004-05-03 2014-03-25 헤르메스 바이오사이언스, 인코포레이티드 약물 전달에 유용한 리포좀
US20090196918A1 (en) * 2008-02-01 2009-08-06 University Of Kentucky Research Foundation Liposomal formulations of hydrophobic lactone drugs in the presence of metal ions
US8389768B2 (en) * 2008-05-19 2013-03-05 The University Of North Carolina At Chapel Hill Methods and compositions comprising novel cationic lipids
WO2010058840A1 (ja) * 2008-11-20 2010-05-27 テルモ株式会社 リポソームからの薬物放出手段および放出性評価法
CN102271659B (zh) * 2009-12-03 2013-09-18 江苏恒瑞医药股份有限公司 伊立替康或盐酸伊立替康脂质体及其制备方法
CN103120645B (zh) * 2009-12-03 2015-03-11 江苏恒瑞医药股份有限公司 伊立替康或盐酸伊立替康脂质体及其制备方法
TWI619496B (zh) 2011-11-03 2018-04-01 台灣微脂體股份有限公司 疏水性喜樹鹼衍生物之醫藥組合物
US10980798B2 (en) 2011-11-03 2021-04-20 Taiwan Liposome Company, Ltd. Pharmaceutical compositions of hydrophobic camptothecin derivatives
KR101842279B1 (ko) * 2012-03-29 2018-03-26 우석대학교 산학협력단 이리노테칸의 안정성증진을 위한 주사제용 조성물
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
EA023079B1 (ru) * 2012-12-24 2016-04-29 Общество С Ограниченной Ответственностью "Технология Лекарств" Способ получения липосомальной формы иринотекана (варианты)
CN104906586A (zh) * 2014-03-10 2015-09-16 中国科学院上海药物研究所 一种盐酸伊立替康复合磷脂组合物、制备方法及其应用
CN105796495B (zh) * 2014-12-29 2020-10-23 南京绿叶制药有限公司 一种盐酸伊立替康脂质体药物组合物及其制备方法
CN105982857B (zh) * 2015-02-09 2019-03-08 湖南科伦药物研究有限公司 一种盐酸伊立替康脂质体组合物及其制备方法
ES2589320B2 (es) * 2015-04-14 2017-06-01 Universidad Politécnica de Madrid Sistema de compartimentación de espacios con membranas enrollables
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
KR101646181B1 (ko) * 2015-08-18 2016-08-05 한양대학교 에리카산학협력단 이리노테칸 함유 이중역상 온도감응성 수용성 겔 조성물
EP3337467B1 (en) 2015-08-20 2020-12-09 Ipsen Biopharm Ltd. Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
IL257149B1 (en) 2015-08-21 2024-07-01 Ipsen Biopharm Ltd Methods for treating pancreatic cancer metastases using combined treatments including liposomal irinotecan and oxaliplatin
CA3001467A1 (en) 2015-10-16 2017-04-20 Ipsen Biopharm Ltd. Stabilizing camptothecin pharmaceutical compositions
BR112019007844A2 (pt) * 2016-11-02 2019-07-16 Ipsen Biopharm Ltd tratamento de câncer gástrico usando terapias de combinação compreendendo irinotecano lipossômico, oxaliplatina, 5-fluoroacila (e leucovorina)
KR102066402B1 (ko) * 2017-12-22 2020-01-15 대화제약 주식회사 이리노테칸 또는 그의 약제학적으로 허용가능한 염을 포함하는 경구투여용 약제학적 조성물
CN109260155B (zh) 2018-11-05 2021-04-06 杭州高田生物医药有限公司 伊立替康脂质体制剂及其制备与应用
KR102185475B1 (ko) * 2019-06-20 2020-12-02 대화제약 주식회사 이리노테칸 자유 염기를 포함하는 경구투여용 약학 조성물
CA3231432A1 (en) * 2021-10-15 2023-04-20 Tianyi Ke Composition containing antitumor drug, and preparation method therefor and use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
IL91664A (en) * 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
EP0721328A4 (en) 1993-09-27 1997-09-17 Smithkline Beecham Corp CAMPTOTHECIN FORMULATIONS
US5827533A (en) 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
US6090407A (en) 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
ATE238039T1 (de) * 1998-09-16 2003-05-15 Alza Corp In liposomen eingeschlossene topoisomerase inhibitoren
JP2001064158A (ja) * 1999-06-25 2001-03-13 Terumo Corp リポソーム
EP1190706B1 (en) * 1999-06-25 2009-05-06 Terumo Kabushiki Kaisha Liposomes
US6352996B1 (en) 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
ES2253398T3 (es) * 2000-06-30 2006-06-01 Inex Pharmaceuticals Corp. Camptotecinas liposomales mejoradas y sus usos.
EP1432402B1 (en) 2001-10-03 2006-11-22 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
DE60237162D1 (de) 2001-10-03 2010-09-09 Celator Pharmaceuticals Inc Liposomenladung mit metallionen
ES2290333T3 (es) * 2001-11-13 2008-02-16 Celator Pharmaceuticals, Inc. Composiciones de vehiculos lipidicos y metodos para la retencion mejorada de farmacos.
JP4555569B2 (ja) * 2001-11-13 2010-10-06 セレーター ファーマシューティカルズ， インコーポレイテッド 増強された血中安定性を有する脂質キャリア組成物
EP1608338A1 (en) 2003-04-02 2005-12-28 Celator Technologies Inc. Pharmaceutical compositions containing active agents having a lactone group and transition metal ions
KR101376895B1 (ko) * 2004-05-03 2014-03-25 헤르메스 바이오사이언스, 인코포레이티드 약물 전달에 유용한 리포좀
US8658203B2 (en) * 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain

Also Published As

Publication number Publication date
EP1752150A4 (en) 2012-06-20
ES2594621T3 (es) 2016-12-21
CA2567857C (en) 2009-12-22
GEP20094620B (en) 2009-02-25
MXPA06013874A (es) 2007-04-25
CN1960729B (zh) 2012-04-11
ECSP067041A (es) 2006-12-29
JPWO2005117878A1 (ja) 2008-04-03
TNSN06395A1 (en) 2008-02-22
WO2005117878A1 (ja) 2005-12-15
CR8768A (es) 2007-08-28
AP2255A (en) 2011-07-21
AU2005249314A1 (en) 2005-12-15
KR20070037440A (ko) 2007-04-04
AU2005249314B2 (en) 2008-09-11
KR100889139B1 (ko) 2009-03-17
US7846473B2 (en) 2010-12-07
EP1752150A1 (en) 2007-02-14
ZA200610204B (en) 2008-01-30
TW200600095A (en) 2006-01-01
CN1960729A (zh) 2007-05-09
US20080069868A1 (en) 2008-03-20
EP1752150B1 (en) 2016-08-31
EA200602246A1 (ru) 2007-04-27
BRPI0511753A (pt) 2008-01-02
CA2567857A1 (en) 2005-12-15
AP2006003837A0 (en) 2006-12-31
NZ551748A (en) 2010-02-26
EA011612B1 (ru) 2009-04-28
NO20066074L (no) 2007-02-28
TWI362931B (en) 2012-05-01
AR049137A1 (es) 2006-06-28
IL179558A0 (en) 2007-07-04
JP4885715B2 (ja) 2012-02-29

Similar Documents

Publication Publication Date Title
UA85099C2 (en) Liposomal irinotecan preparation
Johnston et al. Characterization of the drug retention and pharmacokinetic properties of liposomal nanoparticles containing dihydrosphingomyelin
TW200726485A (en) Liposomal delivery vehicle for hydrophobic drugs
AU1999802A (en) Preparation of large liposomes by infusion into peg
IL140892A (en) Liposomal bupivacaine compositions prepared using an ammonium sulfate gradient
CN103599069B (zh) 一种由pH敏感性多肽修饰的靶向脂质体
AU4711296A (en) Method for loading lipid vesicles
AU3559895A (en) Polyethylene glycol modified ceramide lipids and liposome uses thereof
WO2008109031A3 (en) Liposome carriers for in vivo delivery of fullerenes
WO2002072011A3 (en) Stabilized therapeutic and imaging agents
JPH07112968B2 (ja) リポソ−ム類における抗腫瘍剤類の被包
AU5314194A (en) Cosmetic delivery system for salicylic acid and process for preparation of the same
AU1724097A (en) Lipids and their use, for example, in liposomes
Zhang et al. A novel method to prepare liposomes containing amikacin
WO2013008240A8 (en) Liposomes co-encapsulating a bisphosphonate and an amphipathic agent
ES2303114T3 (es) Metodo para cargar medicamentos en liposomas.
IL313681A (en) Inhibition of ataxia capillary dilation and related protein- RAD3 (ATR)
AU2002340670A1 (en) Lipid carrier compositions and methods for improved drug retention
Margalit et al. Liposomal drug delivery: thermodynamic and chemical kinetic considerations
Bolard et al. Interaction of the anti-Candida amphotericin B (and other polyene antibiotics) with lipids
CN109260155A (zh) 伊立替康脂质体制剂及其制备与应用
Vitiello et al. The iAβ5p β-breaker peptide regulates the Aβ (25–35) interaction with lipid bilayers through a cholesterol-mediated mechanism
Bondeson et al. Promotion of acid-induced membrane fusion by basic peptides. Amino acid and phospholipid specificities
Li et al. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity
De Wolf et al. Effect of doxorubicin on the order of the acyl chains of anionic and zwitterionic phospholipids in liquid-crystalline mixed model membranes: absence of drug-induced segregation of lipids into extended domains